×
Aptorum Group Total Liabilities 2018-2023 | APM
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Aptorum Group total liabilities from 2018 to 2023. Total liabilities can be defined as the total value of all possible claims against the corporation.
View More
Aptorum Group Total Liabilities 2018-2023 | APM
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Aptorum Group total liabilities from 2018 to 2023. Total liabilities can be defined as the total value of all possible claims against the corporation.
Related Stocks
Company Name
Market
Cap
Zoetis (ZTS)
$79.2B
Takeda Pharmaceutical (TAK)
$43.3B
Sandoz Group AG (SDZNY)
$19.5B
Merck (MKKGY)
$19.2B
Astellas Pharma (ALPMY)
$18.2B
United Therapeutics (UTHR)
$16.1B
Summit Therapeutics (SMMT)
$14.7B
Neurocrine Biosciences (NBIX)
$12.1B
Shionogi (SGIOY)
$11.9B
Catalent (CTLT)
$10.7B
Jazz Pharmaceuticals (JAZZ)
$7.1B
Madrigal Pharmaceuticals (MDGL)
$6.9B
Orion OYJ (ORINY)
$6.7B
Corcept Therapeutics (CORT)
$5.7B
Ionis Pharmaceuticals (IONS)
$5.3B
Crinetics Pharmaceuticals (CRNX)
$5.1B
PTC Therapeutics (PTCT)
$3B
Dyne Therapeutics (DYN)
$3B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.6B
Catalyst Pharmaceuticals (CPRX)
$2.6B
Arrowhead Pharmaceuticals (ARWR)
$2.3B
Soleno Therapeutics (SLNO)
$2.2B
NewAmsterdam Pharma (NAMS)
$2.2B
Centessa Pharmaceuticals (CNTA)
$1.9B
Evotec AG (EVO)
$1.8B
Recursion Pharmaceuticals (RXRX)
$1.8B
Xencor (XNCR)
$1.7B
BioCryst Pharmaceuticals (BCRX)
$1.5B
Indivior (INDV)
$1.4B
Harrow (HROW)
$1.4B